Celgene

This very early study tested two drugs, alnuctamab and mezigdomide, together in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink tumors. However, the trial was stopped earl…

This study tested a new drug called CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to check safety, find the best dose, and see if the drug could shrink tumors. Th…

This study tested an oral medication called ozanimod to see if it could help people with moderate to severe Crohn's disease feel better. The trial planned to include 625 adults who had not responded well to other treatments. However, the study was terminated early, so the full re…

This study tested whether the oral drug ozanimod can help people with moderate to severe Crohn's disease maintain symptom control and reduce gut inflammation over 52 weeks. About 550 participants who had already responded to an initial treatment were randomly assigned to receive …

This study was an extension of earlier trials, testing the drug ozanimod in people with moderately to severely active Crohn's disease. The goal was to see if the drug could help patients achieve remission and to track any side effects. The trial was terminated early, meaning it s…

This early-phase trial tested a CAR T cell therapy called bb2121 (ide-cel) combined with other drugs in 21 adults with relapsed or refractory multiple myeloma. The goal was to find a safe dose and see if the combinations could shrink tumors. The study was terminated early, so res…

This study was a large registry that followed over 3,000 people newly diagnosed with multiple myeloma to understand how the disease is managed in everyday practice. Participants received standard treatments prescribed by their own doctors, and researchers collected information on…